Matinas BioPharma Holdings (MTNB) Total Non-Current Liabilities (2014 - 2026)

Matinas BioPharma Holdings (MTNB) has 12 years of Total Non-Current Liabilities data on file, last reported at $726000.0 in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $726000.0, down 79.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $726000.0 (down 79.32% YoY), and the FY2025 annual result was $915000.0, down 61.64% from the prior year.
• Total Non-Current Liabilities fell to $726000.0 in Q1 2026 per MTNB's latest filing, from $915000.0 in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $4.3 million in Q1 2022 and troughed at $726000.0 in Q1 2026.
• A 5-year average of $3.0 million and a median of $3.2 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities increased 21.31% in 2022, then sank 79.32% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $3.9 million in 2022, then declined by 16.94% to $3.2 million in 2023, then fell by 26.3% to $2.4 million in 2024, then tumbled by 61.64% to $915000.0 in 2025, then dropped by 20.66% to $726000.0 in 2026.
• Business Quant data shows MTNB's Total Non-Current Liabilities at $726000.0 in Q1 2026, $915000.0 in Q4 2025, and $1.7 million in Q3 2025.